Here's What to Look For in Pfizer's Upcoming Earnings Report
Pfizer (NYSE: PFE) will report its fourth-quarter results on Feb. 8 and investors are bound to find answers to questions about the company's ongoing performance. Since the early days of the pandemic in January 2020, the stock has risen by more than 54%, beating the market's 40% return. Aside from the usual slew of clinical trial updates and new pipeline projects, all eyes will be on sales of Comirnaty and Paxlovid, the pharma company's two commercialized coronavirus medicines.
Whereas the gains in market share of the Comirnaty jab will be in focus, the outlook for the Paxlovid antiviral pill is more complex. Let's take a moment to consider the most relevant factors for investors as they make buying or selling decisions when the earnings report is published next month.
Image source: Getty Images.
Source Fool.com
